Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Endometriosis (May 2019)

Posted by Matt Breese on May 31, 2019

Find me on:

According to our recent payer coverage analysis for endometriosis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for endometriosis treatments shows that under the pharmacy benefit, around 46% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Endometriosis_2Q2019Data snapshot as of Q2 2019

Trends: ObsEva SA announced in May 2019 that they initiated the Phase III development program of linzagolix, a novel, orally administered gonadotropin-releasing hormone receptor antagonist, to treat women with endometriosis-associated pain.

To read the full Reality Check on Endometriosis treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing